Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
MD Anderson Cancer Center, Houston, Texas France
Institut Paoli Calmettes, Marseille Greece
National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit, Athens Spain
General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante), Alicante Hospital San Pedro de Alcantara, Cáceres Hospital Universitario 12 de Octubre, Madrid Hospital Universitario Quirónsalud, Madrid MD Anderson Cancer Center Madrid, Madrid Clínica Universidad de Navarra, Pamplona Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío), Seville